[144] Amdocs Limited SEC Filing

Rhea-AI Filing Summary

Amdocs Limited (DOX) Form 144 notice: The filing reports a proposed sale of 2,285 shares of Common Stock through Citigroup Global Markets, Inc. (broker address provided) on 09/02/2025. The aggregate market value of the shares to be sold is listed as $195,367.50 and the total number of shares outstanding is reported as 110,000,000. The securities were acquired on 09/02/2025 by a stock option exercise and sale from AMDOCS LIMITED, and the stated nature of payment is compensation. The filer affirms, by signature, that they are not aware of any undisclosed material adverse information about the issuer.

Positive

• Compliance disclosure provided under Rule 144 with broker and transaction details
• Acquisition and payment details are specified (stock option exercise; payment as compensation)
• Filer attests to no undisclosed material adverse information

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine Rule 144 notice for a small block of shares acquired via option exercise and slated for sale through a major broker.

The filing documents a proposed sale of 2,285 common shares routed through Citigroup Global Markets, with an aggregate market value of $195,367.50. Acquisition is reported as a same-day stock option exercise and sale, and payment is identified as compensation. The notice includes the standard representation that no undisclosed material adverse information is known. This filing serves primarily as compliance with Rule 144 and provides basic transaction mechanics rather than new operational or financial data about the issuer.

Corporate Governance Expert

TL;DR: Disclosure meets procedural requirements; content contains limited governance or material signals.

The Form 144 supplies required details: class, broker, share count, aggregate value, outstanding shares, acquisition date and nature, and payment characterization. The signature representation about material adverse information is present. The filing does not disclose the identity of the seller beyond the acquisition source, nor any trading plan or aggregation details. From a governance standpoint, this is a routine insider-related filing with no additional governance actions or disclosures attached.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Citigroup Global Markets, Inc. 390 Greenwich St. New York NY 10013	2285	195367.50	110000000	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	09/02/2025	Stock option exercise and sale	AMDOCS LIMITED			2285	09/02/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the Amdocs Limited Form 144 report for sale (DOX)?

The filing reports 2,285 shares of Common Stock proposed for sale.

When is the proposed sale date and which broker is handling the sale?

The approximate date of sale is 09/02/2025, and the broker listed is Citigroup Global Markets, Inc.

What is the aggregate market value and number of shares outstanding reported?

The aggregate market value is listed as $195,367.50 and shares outstanding are reported as 110,000,000.

How were the securities acquired according to the filing?

The securities were acquired on 09/02/2025 via a stock option exercise and sale from AMDOCS LIMITED.

What is the stated nature of payment for the acquisition?

The filing lists the nature of payment as compensation.